Trethera
$7.9Mtotal raised · 15 rounds on record
$250klatest round · Venture round · Apr 2025 · 18 mo ago
$10.8Mgrants · 11 grants · CORDIS
50+team · employees, estimated range
Funding and backers
Total raised
$7.9M
15 rounds on record
Latest round
$250k
Venture round · Apr 2025 · 18 mo ago
Team
51-200
employees, estimated range
Grants
$10.8M
11 grants · CORDIS
The money's age
Due for its next round
18 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 8, 2025
Won a grant $407k · CORDIS
Sep 3, 2025
Won a grant $905k · CORDIS
Aug 18, 2025
Won a grant $1.2M · CORDIS
Aug 7, 2025
Won a grant $995k · CORDIS
Apr 29, 2025
Raised a round Venture round $250k · SEC Form D
Jul 2, 2024
Won a grant $2.1M · CORDIS
Feb 1, 2024
Won a grant $1.2M · CORDIS
Sep 18, 2023
Won a grant $395k · CORDIS
Aug 1, 2023
Won a grant $602k · CORDIS
Jun 21, 2023
Won a grant $611k · CORDIS
Jun 1, 2023
Won a grant $2M · CORDIS
Sep 30, 2022
Won a grant $368k · CORDIS
Jun 26, 2021
Raised a round Venture round $3.8M · SEC Form D
Feb 25, 2020
Raised a round Venture round $3.3M · SEC Form D
Apr 17, 2019
New executive Jean deKernion, Executive Officer, Director · SEC Form D
Apr 5, 2019
Raised a round Venture round $581k · SEC Form D
2015
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Sep 2025 | $407k | — | CORDIS |
| Grant | Sep 2025 | $905k | — | CORDIS |
| Grant | Aug 2025 | $1.2M | — | CORDIS |
| Grant | Aug 2025 | $995k | — | CORDIS |
| Venture round | Apr 2025 | $250k | — | SEC Form D |
| Grant | Jul 2024 | $2.1M | — | CORDIS |
| Grant | Feb 2024 | $1.2M | — | CORDIS |
| Grant | Sep 2023 | $395k | — | CORDIS |
| Grant | Aug 2023 | $602k | — | CORDIS |
| Grant | Jun 2023 | $611k | — | CORDIS |
| Grant | Jun 2023 | $2M | — | CORDIS |
| Grant | Sep 2022 | $368k | — | CORDIS |
| Venture round | Jun 2021 | $3.8M | — | SEC Form D |
| Venture round | Feb 2020 | $3.3M | — | SEC Form D |
| Venture round | Apr 2019 | $581k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Trethera Corp | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Kenneth Schultz M.D.Executive Officer, DirectorSEC Form D
Carl McKinzieDirectorSEC Form D
Lynne RollinsExecutive OfficerSEC Form D
Jean deKernionExecutive Officer, DirectorSEC Form D
Financials
Total raised
$18.7M
Latest round
Grant
Funding rounds
15
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Grant | 2025 | $407k | Details |
| Grant | 2025 | $905k | Details |
| Grant | 2025 | $1.2M | Details |
| Grant | 2025 | $995k | Details |
| Venture - Series Unknown | 2025 | $250k | Details |
| Grant | 2024 | $2.1M | Details |
| Grant | 2024 | $1.2M | Details |
| Grant | 2023 | $395k | Details |
| Grant | 2023 | $602k | Details |
| Grant | 2023 | $611k | Details |
| Grant | 2023 | $2M | Details |
| Grant | 2022 | $368k | Details |
| Venture - Series Unknown | 2021 | $3.8M | Details |
| Venture - Series Unknown | 2020 | $3.3M | Details |
| Venture - Series Unknown | 2019 | $581k | Details |
People
Kenneth Schultz M.D.
Executive Officer, Director
Carl McKinzie
Director
Lynne Rollins
Executive Officer
Jean deKernion
Executive Officer, Director
Louis Gonda
Director
Laurent Dubois
Director
Timothy Donahue M.D.
Director
R. Quinnell
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
Trethera Selected as a 2026-2027 National Cancer Institute Investor Showcase Company
LOS ANGELES, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (
Read more
Report
Trethera and UCLA Publish Comprehensive Review Highlighting Deoxycytidine Kinase as a Novel Metabolic Target for Cancer Therapy
Read more
Report
Trethera to Highlight Clinical Momentum and Indication Expansion at Biocom Global Partnering & Investor Conference
LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (
Read more
Report
Trethera Successfully Completes Enrollment of Phase 1 Dose Escalation Trial for Patients with Solid Tumors
LOS ANGELES, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (
Read more
Report
Trethera Awarded $3 Million NIH Grant to Advance First-In-Class Drug, TRE-515, for the Treatment of Lupus
Read more
Report
Trethera Secures New License, Strengthening TRE-515 Intellectual Property Portfolio and Extending Market Exclusivity to 2045
LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (
Read more
Report
Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control Immune Cell Activation That Causes Multiple Sclerosis Symptoms in Mice
Read more
Report
Trethera And UCLA Publish Data Demonstrating TRE-515 Ability To Control Immune Cell Activation That Causes Multiple Sclerosis Symptoms In Mice
Read more
Report
Trethera Corporation announces appointment of Timothy "Tim" Donahue, M.D. to the Board of Directors
/PRNewswire/ -- Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for...
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Sherman Oaks
United States
HQ
50-200 est. staff